仙灵骨葆胶囊联合骨质疏松治疗仪治疗骨质疏松症的临床研究  被引量:4

Clinical Study of Xianling Gubao Capsule combined with Therapeutic Instrument for Osteoporosis in Treating Osteoporosis

在线阅读下载全文

作  者:汤小敏[1] 何正保[1] 陈南萍[1] 

机构地区:[1]南昌大学第四附属医院康复医学科,南昌330000

出  处:《中国中医药现代远程教育》2015年第18期35-36,共2页Chinese Medicine Modern Distance Education of China

基  金:江西省南昌市科技计划项目经费资助(No:洪科发计字2012-120第28项)

摘  要:目的观察仙灵骨葆胶囊联合骨质疏松治疗仪治疗骨质疏松症的疗效。方法将120例患者随机分成治疗组60例、对照组60例。对照组仅予口服阿法骨化醇软胶囊和碳酸钙D3片及肌注鲑鱼降钙素,治疗组在此基础上予仙灵骨葆胶囊联合骨质疏松治疗仪,共治疗6个疗程,于疗程结束后参照骨质疏松症的疗效标准对患者进行评估。结果治疗6个疗程后,对照组显效率为16.67%,有效率为83.3%。治疗组显效率为53.3%,有效率为95%,两组间比较χ2=6.142,P=0.045,95%CI[0.000,0.075];O R=7.550,95%CI[0.830,65.930]。结论仙灵骨葆胶囊联合骨质疏松治疗仪治疗骨质疏松症疗效显著。Objective To observe the effect of Xianling Gubao capsule combined with therapeutic instrument for osteoporosis in treating osteoporosis. Methods 120 cases of patients were randomly divided into treatment group of 60 cases and the control group of 60 cases.The control group took orally alfacalcidol soft capsules, calcium carbonate and vitamin tablets and intramuscular salmon calcitonin. The treatment group was given Xianling Gubao capsule combined with therapeutic instrument for osteoporosis on the basis of the control group.They received six courses of treatment. After treatment, patients were evaluated by referring to the standard of curative effect of osteo-porosis. Results After six courses, the complete effective rate and the effective rate of the control group was 16.67 % and 83.3%, respectively. The complete effective rate and the effective rate of the treatment group was 53.3 % and 95%, respectively, between the two groupsχ2 = 6.142, P = 0.045, 95% CI [ 0.000,0.075]; OR = 7.550, 95% CI [ 0.830,65.930]. Conclusion Xianling Gubao capsule combined with therapeutic instrument for osteoporosis in treating osteoporosis had significant effect.

关 键 词:仙灵骨葆胶囊 骨质疏松治疗仪 骨质疏松症 补肾健脾 

分 类 号:R580[医药卫生—内分泌]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象